Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 3/20 | 0.53 |
| ▸ | NPY2R | P49146 | 3/20 | 0.53 |
| ▸ | NPY4R | P50391 | 3/20 | 0.53 |
| ▸ | ACE | P12821 | 2/20 | 0.52 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.51 |
| ▸ | ERAP2 | Q6P179 | 3/20 | 0.50 |
| ▸ | ERAP1 | Q9NZ08 | 3/20 | 0.50 |
| ▸ | LNPEP | Q9UIQ6 | 3/20 | 0.50 |
| ▸ | MC4R | P32245 | 2/20 | 0.50 |
| ▸ | GHSR | Q92847 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29732555 | 1.00 | NPY1R (0.53) | NPY1RNPY2RNPY4RACEKISS1R | |
| SCHEMBL30305296 | 1.00 | NPY1R (0.53) | NPY1RNPY2RNPY4RACEKISS1R | |
| SCHEMBL30339977 | 1.00 | NPY1R (0.53) | NPY1RNPY2RNPY4RACEKISS1R | |
| SCHEMBL30389284 | 1.00 | NPY1R (0.53) | NPY1RNPY2RNPY4RACEKISS1R | |
| SCHEMBL29732607 | 1.00 | NPY1R (0.53) | NPY1RNPY2RNPY4RACEKISS1R | |
| SCHEMBL30388127 | 1.00 | NPY1R (0.53) | NPY1RNPY2RNPY4RACEKISS1R | |
| SCHEMBL29799876 | 1.00 | NPY1R (0.53) | NPY1RNPY2RNPY4RACEKISS1R | |
| SCHEMBL30646173 | 1.00 | NPY1R (0.53) | NPY1RNPY2RNPY4RACEKISS1R | |
| SCHEMBL30646172 | 1.00 | NPY1R (0.53) | NPY1RNPY2RNPY4RACEKISS1R | |
| SCHEMBL29399853 | 1.00 | NPY1R (0.53) | NPY1RNPY2RNPY4RACEKISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250277002-A1 | ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES AND METHODS OF USE | PEPTILOGICS, INC. | 2025-09-04 | — | — | US | claimed |
| US-20240252586-A1 | ENGINEERED ANTIMICROBIAL PEPTIDES AND USAGE THEREOF | PEPTILOGICS, INC. | 2024-08-01 | — | — | US | claimed |
| EP-4401752-A1 | ENGINEERED ANTIMICROBIAL PEPTIDES AND USAGE THEREOF | Peptilogics, Inc. (US) | 2024-07-24 | — | — | EP | claimed |
| EP-4401754-A1 | ENGINEERED ANTIMICROBIAL PEPTIDES AND USAGE THEREOF | Peptilogics, Inc. (US) | 2024-07-24 | — | — | EP | claimed |
| US-20230107222-A1 | ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES AND METHODS OF USE | PEPTILOGICS, INC. | 2023-04-06 | — | — | US | claimed |
| WO-2023044339-A1 | ENGINEERED ANTIMICROBIAL PEPTIDES AND USAGE THEREOF | PEPTILOGICS, INC. (US) | 2023-03-23 | — | — | WO | claimed |
| WO-2023044423-A1 | ENGINEERED ANTIMICROBIAL PEPTIDES AND USAGE THEREOF | PEPTILOGICS, INC. (US) | 2023-03-23 | — | — | WO | claimed |
| US-20220332777-A1 | Methods and Compositions for Treatment of Antibiotic-Resistant Bacterial Infections | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2022-10-20 | — | — | US | claimed |
| US-20250320266-A1 | Methods and Compositions for Treatment of Antibiotic-Resistant Bacterial Infections | UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) | 2025-10-16 | — | — | US | disclosed |
| US-12371463-B2 | Methods and compositions for treatment of antibiotic-resistant bacterial infections | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-07-29 | — | — | US | disclosed |
| US-20240317809-A1 | Engineered Antimicrobial Peptides and Usage Thereof | UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) | 2024-09-26 | — | — | US | disclosed |
| EP-4401752-A1 | ENGINEERED ANTIMICROBIAL PEPTIDES AND USAGE THEREOF | Peptilogics, Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| CN-118265536-A | Engineered antibacterial peptides and uses thereof | 肽逻辑公司 | 2024-06-28 | — | — | CN | disclosed |
| US-20240115654-A1 | INTRAVENOUS ADMINISTRATION OF ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES | PEPTILOGICS, INC. | 2024-04-11 | — | — | US | disclosed |
| WO-2023044423-A1 | ENGINEERED ANTIMICROBIAL PEPTIDES AND USAGE THEREOF | PEPTILOGICS, INC. (US) | 2023-03-23 | — | — | WO | disclosed |
| US-20220332777-A1 | Methods and Compositions for Treatment of Antibiotic-Resistant Bacterial Infections | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2022-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115654-A1 | INTRAVENOUS ADMINISTRATION OF ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES | IAPP, VIP, NGLY1 | NPY1R 2841/4885NPY2R 3413/4885NPY4R 3117/4885 |
| US-20250277002-A1 | ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES AND METHODS OF USE | NGLY1, PRF1, LNPEP | NPY1R 3504/4885NPY2R 3813/4885NPY4R 3510/4885 |
| US-20230107222-A1 | ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES AND METHODS OF USE | NGLY1, PRF1, LNPEP | NPY1R 3504/4885NPY2R 3813/4885NPY4R 3510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.